Circulating tumor cells market seen doubling to $28.68B by 2031

Mordor Intelligence projects the global circulating tumor cells market will rise from $14.69 billion in 2026 to $28.68 billion by 2031, driven by cancer prevalence, precision medicine demand and better liquid biopsy tools. North America leads now, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - The circulating tumor cells market is tied to cancer research, diagnosis and treatment monitoring. - Faster growth in liquid biopsy tools could expand the use of blood-based testing in oncology. - Diagnostic technology providers, research labs, hospitals and biopharmaceutical companies stand to gain from broader adoption.

What happened: - Mordor Intelligence estimated the global circulating tumor cells market at $14.69 billion in 2026. - Mordor Intelligence projected the market will reach $28.68 billion by 2031. - The forecast implies a 14.31% compound annual growth rate from 2026 to 2031. - The company linked the outlook to rising cancer prevalence, precision medicine demand and technical progress in tumor cell isolation and detection.

The details: - Circulating tumor cells are cancer cells that detach from primary or metastatic tumors and enter the bloodstream. - CTC isolation and characterization can help researchers study tumor biology and disease progression. - Oncology research is increasingly using CTC analysis to study tumor heterogeneity and treatment resistance. - Advances in microfluidic platforms, single-cell analysis and artificial intelligence-enabled imaging are strengthening liquid biopsy workflows. - Improved cell enrichment, microfluidic separation, immunomagnetic isolation and imaging-based detection are expanding what CTC analysis can do. - Molecular analysis and single-cell sequencing are helping researchers compare genetic and protein-level differences between tumor cells. - CTC analysis is being explored for prognostic assessment, therapy monitoring, minimal residual disease research and drug development. - Pharmaceutical and biotechnology companies are also using CTC-based approaches in clinical research and biomarker discovery. - North America accounted for 43.92% of global revenue in 2025. - Europe remains an established market supported by oncology research networks and collaboration between academic institutions and pharmaceutical companies. - Asia-Pacific is projected to be the fastest-growing region, with a 15.82% CAGR from 2026 to 2031. - The Middle East and Africa and South America are emerging markets as oncology services and research capabilities expand. - The report is available in Japanese, French, German, Spanish and Portuguese, with links provided in the source release.

Between the lines: - The market outlook reflects a broader shift toward personalized cancer care and less invasive testing. - Competition is likely to center on capture performance, analytical sensitivity, workflow efficiency and downstream molecular analysis. - Partnerships with pharmaceutical companies and research institutions remain important for validation and adoption. - Soumya Goud, senior research manager at Mordor Intelligence, said decision-makers benefit from research grounded in transparent sourcing, consistent validation and balanced market assessment.

What's next: - More product development should focus on higher-quality cell isolation, automated analysis and integrated molecular profiling. - Regional growth will likely track cancer incidence, diagnostic infrastructure and precision oncology investment. - Recent research on deep-learning CTC phenotyping and machine-learning biomarkers suggests more automation and broader clinical research use ahead. - Mordor Intelligence expects continued expansion in research, clinical applications and companion diagnostics as the field matures.

The bottom line: - CTC analysis is moving from a niche research tool toward a broader liquid biopsy market with strong global growth potential.